Cancer Tumor Biomarker-Based Assay Market Trends, Leading Companies, Company Revenue / Sales Performance, Manufacturing Capacity, Defense Contracts, Export Analysis, Pricing Metrics, Competitive Landscape, and Industry Outlook

Cancer Tumor Biomarker Based Assay Market Size, Share, Trends, and Growth Forecast 2035

The cancer tumor biomarker-based assays market is forecasted to expand from USD 14.15 billion in 2026 to USD 33.91 billion by 2035, growing at a CAGR of 10.20% from 2027 to 2036.

Key Takeaways

Market Size & Growth Outlook

• Market size in 2025: USD 12.84 billion
• Estimated market size in 2026: USD 14.15 billion
• Projected market size by 2035: USD 33.91 billion
• CAGR (2026-2035): 10.20%

Regional Market Spotlight

• North America led the market with a 43.60% (USD 5.60 billion) share in 2025.
• Europe accounted for 26.40% (USD 3.39 billion) of the market in 2025.
• Asia Pacific accounted for 22.80% (USD 2.93 billion) of the market in 2025 and is projected to be the fastest-growing region, at a CAGR of 11.51% from 2025 to 2035.

Segmental Spotlight

• By cancer type, Breast Cancer accounted for 24.60% (USD 3.16 billion) in 2025.
• By biomarker type, Genetic/Genomic accounted for 44.80% (USD 5.75 billion) in 2025.
• By end use, Hospitals & Cancer Centers accounted for 46.20% (USD 5.93 billion) in 2025.

Cancer Tumor Biomarker-Based Assay Market Size and Forecast, 2025-2035 (USD Billion)

The cancer tumor biomarker-based assays market will be valued at USD 33.91 billion in 2035, rising from the estimated value of USD 12.84 billion in 2025, because with every new drug and new immune therapy approved by the Food and Drug Administration (FDA), another biomarker test is required, and more patients are prescribed genomic profiling. The serum tumor markers are extensively employed and, along with liquid biopsy and methylation testing, will bring the market up to the level of USD 20.87 billion in 2030 with 10.20% CAGR between 2026 and 2035.

• Analyst View: The forecast is based on a calculation involving the number of cancer cases by tumour types, multiplied by biomarker test penetration for diagnosis, treatment selection and monitoring, and by the costs of the various protein, genomic and epigenetic assays. Penetration of these tests depends on guidelines, the need for the tests in the approval of drugs, and follow-on biomarker serum tests such as PSA, CA-125, CEA, and CA 19-9. This was compared to the oncology test revenues of top diagnostics and genomic test companies as well as industry estimates, thus putting the base year slightly above the others.

Market Trends

• New cancer drugs are approved with paired biomarker tests.
• Comprehensive NGS panels are replacing single-gene tests.
• Liquid biopsy is used when tissue is limited.
• PD-L1 testing is expanding to more tumour types.
• Methylation-based tests are entering screening and classification.
• Automated immunoassays keep serum markers central to monitoring.

Drivers, Restraints and Opportunities

Driver

Cancers are increasing in their incidence, and at the same time, the number of targeted and immune therapies, which involve a biomarker test, continues to increase. Many advanced cancers need clinical guidelines involving genomic profiling, including cancers of the lung, colorectal region, breast, and prostate. Drugs approved through companion diagnostics become mandatory tests for patient selection. Serum tumor markers are still used extensively for treatment monitoring and recurrence.

Restraints

The reimbursement of genomic panel tests and liquid biopsy is uneven in various nations and payers. The low specificity of some serum tumour markers limits their applicability in the screening process. The tissue sample sizes may be too small for conducting several tests. Companion diagnostics regulations increase costs and time delays. There is limited laboratory capability and bioinformatics experience in many areas.

Opportunities

Multi-cancer early detection tests and methylation tests can create a large screening market. Liquid biopsy tests will increase testing options for individuals with insufficient tissue. Drug companies' collaboration will help gain the position of companion diagnostic tests in the case of novel therapies. Automation and decentralization of genomic tests will help to conduct profiling at community hospitals. Growth potential in Asia exists.

Market Segmentation: 2025 Share and Value

Cancer Tumor Biomarker-Based Assay Market by Cancer Type 2025 Share & Size

Note: 2025 is the base year.

Sources: Expert interviews, secondary sources, Precedence Research database, and Precedence Research analysts.

Breast cancer captured 24.60% (USD 3.16 billion) in 2025 because tests for HER2, hormone receptors, PIK3CA, and gene expression are performed on the majority of patients. Lung cancer is the fastest-growing segment because non-small cell lung cancer patients have to be tested for EGFR, ALK, ROS1, KRAS, PD-L1, and other biomarkers before they can receive any therapy, which is usually done via NGS. Other cancers, including melanoma, bladder cancer, and blood cancer, constitute 18.40% (USD 2.36 billion); colorectal cancer is responsible for 15.40% (USD 1.98 billion) because of tests for KRAS, BRAF, MSI, and screening tests; prostate cancer is the cause of 13.20% (USD 1.69 billion) because of PSA and genomic risk testing; and ovarian cancer is responsible for 5.60% (USD 0.72 billion).

Cancer Tumor Biomarker-Based Assay Market by Biomarker Type 2025 Share & Size

Note: 2025 is the base year.

Sources: Expert interviews, secondary sources, Precedence Research database, and Precedence Research analysts.

The genetic and genomic assays made up 44.80% (USD 5.75 billion) in 2025, representing the most rapidly expanding segment due to the need for mutation, fusion, and gene expression assays and NGS panels, which analyze a large number of genes. Protein assays were valued at 42.60% (USD 5.47 billion) and consisted of serum tumor markers that are conducted by high-throughput immunoassays, as well as immunohistochemistry biomarkers like PD-L1 and HER2 used as companion diagnostics. Epigenetic assays made up 7.40% (USD 0.95 billion), whereas other biomarkers comprised 5.20% (USD 0.67 billion).

Cancer Tumor Biomarker-Based Assay Market by End Use 2025 Share & Size

Note: 2025 is the base year.

Sources: Expert interviews, secondary sources, Precedence Research database, and Precedence Research analysts.

Hospital and cancer centers contributed USD 5.93 billion (46.20%) in 2025 owing to immunohistochemistry and other serum markers being performed in hospital pathology departments. Diagnostic labs made up USD 5.73 billion (44.60%) and have been experiencing more rapid growth due to complex genomic and liquid biopsy tests being referred to specialist reference laboratories. Others, including research institutions and pharmaceutical trial laboratories, comprised USD 1.18 billion (9.20%).

• Analyst View: Values were estimated across segments based on allocation of cancer cases and test frequency by tumour type to biomarker categories and sites of testing on the basis of average test price. Genomic tests lead since they have higher prices per test; however, protein tests lead in volume. We foresee that genomic and epigenetic tests, lung cancer, and reference laboratories will take market share.

Regional Analysis

Cancer Tumor Biomarker-Based Assay Market by Region 2025 Share & Size

Note: 2025 is the base year.

Sources: Expert interviews, secondary sources, Precedence Research database, and Precedence Research analysts.

North America accounted for 43.60% (USD 5.60 billion) in 2025. Companion diagnostic and genomic profiling coverage drives testing. Large reference laboratories handle complex assays. Most new biomarker-drug pairs launch here first.

Europe accounted for 26.40% (USD 3.39 billion) in 2025. National cancer plans and molecular tumour boards support testing. NGS reimbursement is expanding in Germany and France. The EU IVD Regulation is raising evidence requirements.

Asia Pacific accounted for 22.80% (USD 2.93 billion) in 2025 and is the fastest-growing region. High lung cancer incidence with EGFR mutations drives testing. Genomic testing is expanding in China, Japan, and South Korea. New oncology drug launches add companion testing.

Latin America accounted for 4.20% (USD 0.54 billion) in 2025. Private laboratories in Brazil and Mexico lead testing. Access to targeted therapies is gradually improving.

The Middle East and Africa accounted for 3.00% (USD 0.39 billion) in 2025. Specialist cancer centres in the Gulf drive demand. Testing access is limited across much of Africa.

Analyst View: The regional shares have been derived based on the number of cancer patients, the rate of biomarker tests performed, and the cost of the assay in each region. The reason why North America is considered to be the leader is that it has very high testing rates as well as genomic test reimbursement. We have attributed the Asia Pacific region the highest growth premium.

Top 10 Companies in the Cancer Tumor Biomarker-Based Assay Market

Note: Company revenues and shares are 2025 estimates.

Sources: Company press releases, expert interviews, secondary sources, Precedence Research database and Precedence Research analysts.

Roche Diagnostics dominated the cancer tumor biomarker-based assay market with an estimated 16.36% (USD 2.10 billion) share of revenue, followed by Exact Sciences with 7.17% (USD 0.92 billion) and Guardant Health with 6.70% (USD 0.86 billion). Roche Diagnostics dominates because of its extensive oncology portfolio of assays such as Elecsys serum tumour markers on a substantial number of large analyzers, VENTANA immuno-histochemistry companion diagnostics, and Foundation Medicine genomic profiling. Exact Sciences dominates colorectal cancer screening tests and breast cancer gene expression tests, while Guardant Health dominates blood-based liquid biopsies for treatment selection and monitoring. Thermo Fisher Scientific, Illumina, and QIAGEN dominate genomic and PCR assays utilized as companion diagnostics, Agilent dominates PD-L1 immunohistochemistry, and Abbott and Siemens Healthineers dominate serum tumor marker testing.

The top 10 companies accounted for an estimated 57.63% (USD 7.40 billion) of 2025 revenue, while the remaining 42.37% (USD 5.44 billion) was shared among genomic testing laboratories, regional assay makers, immunohistochemistry suppliers and liquid biopsy start-ups. The cancer tumor biomarker-based assay market is somewhat fragmented, and competition lies in the approval of companion diagnostics related to new drugs, panel range, turnaround time, sample collection, and reimbursements. Having collaborations with pharma companies would be an added advantage, as the test that is approved along with a new drug becomes the standard procedure for patient selection.

Recent Developments

• May 2026: Guardant Health received FDA approval for Guardant360 Liquid CDx, an updated liquid biopsy test analysing more than 740 genes, with prior companion diagnostic claims transferred to the new test.
• February 2026: The FDA approved Agilent's PD-L1 IHC 22C3 pharmDx as a companion diagnostic for Keytruda in PD-L1-expressing ovarian, fallopian tube and primary peritoneal cancer, its seventh companion use with Keytruda.

Cancer Tumor Biomarker Based Assay Market Segments

By Cancer Type

• Breast Cancer
• Lung Cancer
• Others
• Colorectal Cancer
• Prostate Cancer
• Ovarian Cancer

By Biomarker Type

• Genetic/Genomic
• Protein
• Epigenetic
• Others

By End Use

• Hospitals & Cancer Centers
• Diagnostic Laboratories
• Others

By Region

• North America (U.S., Canada, Mexico)
• Europe (Germany, U.K., France, Italy, Spain, Rest of Europe)
• Asia Pacific (China, Japan, India, South Korea, Taiwan, Rest of Asia Pacific)
• Latin America (Brazil, Argentina, Rest of Latin America)
• Middle East & Africa (GCC, South Africa, Rest of MEA)

Research Methodology

The cancer tumor biomarker-based assay market was estimated as protein, genetic, genomic, epigenetic, and other types of cancer biomarker assays for the purpose of screening, diagnosing, treating, and monitoring globally. The base year for 2025 was developed using a bottom-up approach based on cancer patients by type, rate of biomarker testing, and cost of testing, and then was confirmed using a top-down approach through the oncology testing revenues of major diagnostic and genomic testing firms. Values for the segments, regions, and companies were then allocated according to cancer types, biomarker types, end-users, and geographic testing activities. Major assumptions and inputs were then verified through cross-checks with company reports, regulatory, and industry data, as well as published third-party estimates, with any conflicting assumptions or estimates being removed. Figures for segments, regions, and companies were reconciled to the base year 2025, and the forecast period of 2026-2035, calculated at a constant CAGR from the 2025 base year, was recomputed.

Analyst View Overall Market

The cancer tumor biomarker-based assay market is strongly correlated with the development of targeted and immunotherapies, with genomic assays having the highest added value. The projected market correlates with the number of cancers, rates of testing, and assay costs depending on the tumor and biomarkers. Companion diagnostics, liquid biopsy, and early diagnosis assays will be driving the growth, while non-uniform reimbursement and low tissue and lab capacities pose risks.

Sources and References

1. Fierce Biotech. "Agilent companion diagnostic lands FDA nod alongside Keytruda's latest cancer approval". 2026-02. PD-L1 IHC 22C3 ovarian cancer companion diagnostic. https://www.fiercebiotech.com/medtech/agilent-lands-fda-nod-companion-diagnostic-keytrudas-latest-cancer-approval
2. Clinical Lab Products. "FDA approves VENTANA PD-L1 as a CDx for NSCLC subtype". 2023-03-09. VENTANA PD-L1 SP263 for Libtayo. https://clpmag.com/disease-states/cancer/lung-cancer/fda-approves-ventana-pd-l1-as-a-cdx-for-nsclc-subtype/
3. Fujirebio Diagnostics. "Fujirebio Diagnostics announces FDA clearance of Lumipulse G CA19-9-N assay". 2019-12-17. CA19-9 assay clearance. https://www.fujirebio.com/en-us/news-events/fujirebio-diagnostics-announces-fda-clearance-of-lumipulser-g-ca199n-assay
4. Patient Worthy. "Guardant Health secures FDA clearance for expanded liquid biopsy test". 2026-05-24. Guardant360 Liquid CDx approval. https://patientworthy.com/2026/05/24/guardant-health-secures-fda-clearance-for-expanded-liquid-biopsy-test/